Health Canada Approves Remsima™ SC for the Treatment of Inflammatory Bowel Disease (IBD)
Remsima™ SC, the first subcutaneous infliximab, now approved in Canada for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD)1 The approval is based on results from the LIBERTY2,3 studi